Hyperleptinaemia, insulin resistance and survival in peritoneal dialysis patients

Nephrology

Volumn 20, Issue 9, 2015, Pages 617-624

  Cao, Liou ^a   Mou, Shan ^a   Fang, Wei ^a   Gu, Leyi ^a   Huang, Jiaying ^a   Gu, Aiping ^a   Qian, Jiaqi ^a   Ni, Zhaohui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

hyperleptinaemia; insulin resistance; leptin; mortality; peritoneal dialysis

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CA 125 ANTIGEN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TRIACYLGLYCEROL; URIC ACID; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; INSULIN; LIPID;

ADULT; AGE DISTRIBUTION; ARTERIAL PRESSURE; ARTICLE; ASSESSMENT OF HUMANS; BODY MASS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HYPERLEPTINEMIA; INSULIN RESISTANCE; LEUKOCYTE COUNT; LIPID ANALYSIS; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MIDDLE AGED; MORTALITY; NORMALIZED PROTEIN CATABOLIC RATE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; ADVERSE EFFECTS; AGE; AGED; BLOOD; CAUSE OF DEATH; KAPLAN MEIER METHOD; KIDNEY DISEASES; METABOLISM; TIME FACTOR; TREATMENT OUTCOME; UPREGULATION;

ADULT; AGE FACTORS; AGED; BIOMARKERS; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CAUSE OF DEATH; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; LEPTIN; LIPIDS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84939439372     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12491     Document Type: Article

References (28)

1. Duong U, Mehrotra R, Molnar MZ, etal. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin. J. Am. Soc. Nephrol. 2011; 6: 1041-1048.
2. Cotovio P, Rocha A, Rodrigues A,. Peritoneal dialysis in diabetics: There is room for more. Int. J. Nephrol. 2011; 2011.
3. Goldstein BJ,. Insulin resistance as the core defect in type 2 diabetes mellitus. Am. J. Cardiol. 2002; 90: 3-10.
4. Wang T, Heimbürger O, Cheng H, Bergstroem J, Lindholm B,. Amphotericin B does not increase peritoneal fluid removal. Adv. Perit. Dial. 1998; 14: 3-10.
5. Szeto C-C, Chow K-M, Leung C-B, etal. Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis. Nephrol. Dial. Transplant. 2007; 22: 1697-1702.
6. Tuzcu A, Bahceci M, Yilmaz ME, Turgut C, Kara IH,. The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease. Saudi Med. J. 2005; 26: 786-791.
7. Ahima RS, Flier JS,. Leptin. Annu. Rev. Physiol. 2000; 62: 413-437.
8. Shankar A, Syamala S, Xiao J, Muntner P,. Relationship between plasma leptin level and chronic kidney disease. Int. J. Nephrol. 2012; 2012: 269532.
9. Steppan CM, Bailey ST, Bhat S, etal. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
10. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM,. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes. Res. 2002; 10: 1-5.
11. Pang S, Le Y,. Role of resistin in inflammation and inflammation-related diseases. Cell. Mol. Immunol. 2006; 3: 29-34.
12. Gawkrodger D, Ferguson A, Barnetson R,. Nutritional status in patients with dermatitis herpetiformis. Am. J. Clin. Nutr. 1988; 48: 355-360.
13. Bodnar DM, Busch S, Fuchs J, etal. Estimating glucose absorption in peritoneal dialysis using peritoneal equilibratin tests. Adv. Perit. Dial. 1993; 9: 114-118.
14. Krishnasamy R, Badve SV, Hawley CM, etal. Daily variation in death in patients treated by long-term dialysis: Comparison of in-center hemodialysis to peritoneal and home hemodialysis. Am. J. Kidney Dis. 2013; 61: 96-103.
15. Henriques VT, Martinez EZ, Divino-Filho JC, Pecoits-Filho R, Cardeal da Costa JA,. Increase in BMI over time is associated with fluid overload and signs of wasting in incident peritoneal dialysis patients. J. Ren. Nutr. 2013; 23: e51-57.
16. Enriori PJ, Evans AE, Sinnayah P, Cowley MA,. Leptin resistance and obesity. Obesity 2006; 14: 254S-258S.
17. Kadowaki T, Yamauchi T,. Adiponectin and adiponectin receptors. Endocr. Rev. 2005; 26: 439-451.
18. Amira OC, Naicker S, Manga P, etal. Adiponectin and atherosclerosis risk factors in African hemodialysis patients: A population at low risk for atherosclerotic cardiovascular disease. Hemodial. Int. 2012; 16: 59-68.
19. Johnson DW, Armstrong K, Campbell SB, etal. Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology 2007; 12: 391-398.
20. Rossum C, Hoebee B, Baak MA, Mars M, Saris WH, Seidell JC,. Genetic variation in the leptin receptor gene, leptin, and weight gain in young Dutch adults. Obes. Res. 2003; 11: 377-386.
21. Wang AY-M, Woo J, Lam CW-K, etal. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J. Am. Soc. Nephrol. 2003; 14: 1871-1879.
22. McLaughlin T, Abbasi F, Lamendola C, etal. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002; 106: 2908-2912.
23. Johansen KL, Mulligan K, Tai V, Schambelan M,. Leptin, body composition, and indices of malnutrition in patients on dialysis. J. Am. Soc. Nephrol. 1998; 9: 1080-1084.
24. Furuya R, Odamaki M, Kumagai H, Hishida A,. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol. Dial. Transplant. 2006; 21: 494-498.
25. Nascimento MM, Suliman ME, Silva M, etal. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: A placebo-controlled study. Perit. Dial. Int. 2010; 30: 336-342.
26. Hyun E, Ramachandran R, Hollenberg MD, Vergnolle N,. Mechanisms behind the anti-inflammatory actions of insulin. Crit. Rev. Immunol. 2011; 31: 307-340.
27. Freedman BI, Andries L, Shihabi ZK, etal. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin. J. Am. Soc. Nephrol. 2011; 6: 1635-1643.
28. Fang W, Yang X, Kothari J, etal. Patient and technique survival of diabetics on peritoneal dialysis: One-center's experience and review of the literature. Clin. Nephrol. 2008; 69: 193-200.